About the Sponsor
With a new diagnosis every 14 seconds, breast cancer is the most common cancer among women globally. Breast cancer is a collection of diseases comprised of different subtypes and stages, each requiring unique treatment approaches. Metastatic breast cancer (MBC) is the most advanced stage of the disease and is currently incurable. Despite scientific advancements that have extended survival for people with MBC, there remains a need for innovative therapies that improve outcomes by overcoming treatment resistance, preventing disease recurrence and enhancing tolerability and patient quality of life.
Pfizer has been a leader in breast cancer for 25 years, with our first regulatory approvals in 1999. Today we have five medicines and one biosimilar approved to treat different subtypes of breast cancer. Our portfolio includes IBRANCE® (palbociclib), the first cyclin-dependent kinase (CDK) 4/6 inhibitor which helped revolutionize the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor-negative (HER2-) MBC, and TUKYSA® (tucatinib), an important treatment option for people with human epidermal growth factor receptor 2-positive (HER2+) MBC.
We are advancing a deep pipeline of innovative molecules designed to address unmet needs across multiple lines of therapy and subtypes in breast cancer. We aim to provide new treatment backbones in HR+ breast cancer with our next-generation cell cycle inhibitor and endocrine therapies atirmociclib, a highly selective CDK4 inhibitor, and vepdegestrant, a proteolysis-targeting chimera (PROTAC) estrogen receptor protein degrader in development with Arvinas. With a focus on small molecules and antibody-drug conjugates (ADCs), we are also exploring novel targets as we work to overcome challenges with endocrine resistance mechanisms, such as PF-07248144, a lysine acetyltransferase 6 (KAT6) selective inhibitor and PF-07104091, a novel CDK2-selective inhibitor.
We know that caring for people with breast cancer is about more than just our medicines. We’ve built strong relationships with the breast cancer community to inform, guide, and expand our work, partnering with patient advocacy groups and medical societies around the world to better understand and support people with breast cancer, including addressing the unique needs and disparities in care for people living with MBC.
Pfizer is proud of our leadership in breast cancer, but our work is far from finished. Driven by science and with a focus on addressing patient needs across the spectrum of disease, we are working to accelerate breakthroughs that help people with breast cancer live better and longer lives.
